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Antibiotics blocking bacterial cell wall assembly
(b-lactams and glycopeptides) are facing a challenge
from the progressive spread of resistant pathogens.
Lantibiotics are promising candidates to alleviate
this problem. Microbisporicin, the most potent
antibacterial among known comparable lantibiotics,
was discovered during a screening applied to un-
common actinomycetes. It is produced byMicrobis-
pora sp. as two similarly active and structurally re-
lated polypeptides (A1, 2246-Da and A2, 2230-Da)
of 24 amino acids linked by 5 intramolecular thioether
bridges. Microbisporicin contains two posttransla-
tional modifications that have never been reported
previously in lantibiotics: 5-chloro-trypthopan and
mono- (in A2) or bis-hydroxylated (in A1) proline.
Consistent with screening criteria, microbisporicin
selectively blocks peptidoglycan biosynthesis, caus-
ing cytoplasmic UDP-linked precursor accumulation.
Considering its spectrum of activity and its efficacy
in vivo, microbisporicin represents a promising anti-
biotic to treat emerging infections.
INTRODUCTION
Infections caused by Gram-positive pathogens constitute a
major burden on patients and healthcare systems globally.
This scenario is further complicated by the emergence of re-
sistant strains no longer predictably susceptible to standard
first-line antimicrobials, such as oxacillin or vancomycin
(Johnson and Woodford, 2002). In particular, methicillin-
resistant Staphylococcus aureus (MRSA) strains are often multi-
resistant to several antibiotic classes. They represent the major
cause of serious infections acquired in the hospital, and have
recently emerged in communities. This has resulted in the wide
use of glycopeptides, such as vancomycin and teicoplanin, as
drugs of last resort for seriousMRSA infections. However, glyco-
peptide tolerance has now emerged, too, and highly vancomy-
cin-resistant clinical S. aureus (VRSA) isolates have recently
been described (Johnson and Woodford, 2002; Appelbaum,
2006). Medical need is driving the search for novel, and more ef-22 Chemistry & Biology 15, 22–31, January 2008 ª2008 Elsevier Ltdfective antibiotics against MRSA, and hopefully also for treating
other clinically important Gram-positive pathogens. In this con-
text, we recently devised a screening strategy for identifying
inhibitors of bacterial cell wall biosynthesis, different from b-
lactams and glycopeptides, and thus potentially capable of
overcoming existing resistance mechanisms (Castiglione et al.,
2007).
The screening was applied to the Vicuron library of 120,000
broth extracts obtained by fermenting 40,000 uncommon
actinomycetes isolated in the environment (Castiglione et al.,
2007; Lazzarini et al., 2001). The primary assay was devised to
identify microbial extracts containing peptidoglycan (PG)
biosynthesis inhibitors on the basis of their differential activity
against S. aureus and its L form (Castiglione et al., 2007; Somma
et al., 1977). Secondary selection was oriented to discard those
extracts containing b-lactams or glycopeptides. It was based on
whether antimicrobial activity against S. aureus could be
reversed by a b-lactamase cocktail or by adding D-Ala-D-Ala af-
finity resin (Corti et al., 1985). Through this approach, five novel
lantibiotics were identified. In this paper, we report on the struc-
ture elucidation and biological profiling of the most potent
among these novel lantibiotics, named microbisporicin. Its
structure is original, containing two posttranslational modifica-
tions that have not been reported previously in lantibiotics.
Microbisporicin’s antimicrobial activity is superior to compara-
ble, known lantibiotics.
Lantibiotics are ribosomally synthesized and posttranslation-
ally modified peptides produced by Gram-positive bacteria
(Jung, 1991). They contain thioether intramolecular cross-linked
amino acids, termed lanthionines (Lans) or 3-methyllanthionines
(Melans), in addition to the unsaturated amino acids, 2,3-didehy-
droalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb) (Chatterjee
et al., 2005; Cotter et al., 2005; Pag andSahl, 2002). Traditionally,
these peptides have been classified, on the basis of structural
and functional aspects, as being either type A or type B lantibiot-
ics. Nisin, which has been used in the dairy industry for over
40 years, was considered the prototype for the flexible amphi-
philic type A lantibiotics, which act by forming pores in the cell
membrane of susceptible cells (Jung, 1991). It is a 3353 Da
cationic, elongated peptide, 34 amino acids long, containing
five intramolecular ring structures, which is produced by Lacto-
coccus lactis sub lactis (Jung, 1991; Chatterjee et al., 2005;
Pag and Sahl, 2002). In contrast, type B lantibiotics, such as
mersacidin (Chatterjee et al., 1992), actagardine (Somma et al.,All rights reserved
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Seelig, 2003), are more globular and compact in structure, and
act by inhibiting the function of various enzymes by binding to
membrane lipids. Mersacidin (1825 Da) (Chatterjee et al., 1992)
and actagardine (also termed gardimycin) (1890 Da) (Somma
et al., 1977; Parenti et al., 1976) are structurally similar tetracyclic
hydrophobic peptides, 20 and 19 residues long, containing four
intramolecular thioether rings, which are produced by a Bacillus
strain and by an Actinoplanes species, respectively. They inhibit
PG synthesis by binding to lipid II, the essential membrane-
bound precursor for cell wall formation (Brotz et al., 1998a). Cin-
namycin-like peptides, 19 amino acids long, produced by Strep-
tomyces spp. show distinct functions, inhibiting phospholipases
by binding phosphatidylethanolamine (Machaidze and Seelig,
2003). However, the distinction between type A and type B lanti-
biotics has become blurred, as it was observed that nisin inter-
acts in a highly specific manner with lipid II (Breukink et al.,
1999). Lipid II, indeed, acts as a docking molecule for nisin,
and energetically facilitates the formation of membrane pores
(Breukink et al., 1999; Hasper et al., 2006). A more recent classi-
fication of lantibiotics in different subgroups has been proposed
based on the organization of their biosynthetic genes and en-
zymes, rather than on the activity profile or three-dimensional
structure (Chatterjee et al., 2005; Cotter et al., 2005).
The renewed interest in the chemotherapeutic potential of
antibacterial lantibiotics that inhibit cell wall synthesis originates
from the fact that they are effective in treating infections sus-
tained by MRSA and that they did not show cross-resistance
with glycopeptides (Castiglione et al., 2007; Cotter et al.,
2005). In fact, their complex with lipid II differs greatly from the
glycopeptides-lipid II complex, and does not involve theC-termi-
nal D-alanyl-D-alanine (D-Ala-D-Ala) moiety of the pentapeptide
side chain of the lipid intermediate, but, rather, equally blocks
access of the transglycosylase to its substrate (Brotz et al.,
1997, 1998a). In this light, microbisporicin discoverymay provide
additional insights into the molecular determinants of the biolog-
ical activity of lipid II-targeting antibiotics.
RESULTS
Identification, Production, and Purification
of Microbisporicin
Microbisporicin, previously patented as antibiotic 107891
(Lazzarini et al., 2005), was discovered during the screening
approach described elsewhere (Castiglione et al., 2007), which
was applied to the Vicuron collection and devised to target novel
PG biosynthesis inhibitors. The microbisporicin-containing
microbial extract was found to be at least 8-fold more active
against S. aureus than against its L form and insensitive to the
addition of a b-lactamase cocktail or D-Ala-D-Ala affinity resin,
according to the primary and secondary screening criteria
(data not shown). It is produced by the actinomycete, Microbis-
pora ATCC PTA-5024, as two factors (microbisporicin A1 and
A2), typically in a 60:40 ratio (see Experimental Procedures for
the fermentation and purification conditions). The antibiotic
was found either in the supernatant of the harvested broth or
associated with themycelium, with a total estimated productivity
ranging from 10 to 20 mg/l of culture. It was purified by multistep
chromatography. Microbisporicin remained substantially stableChemistry & Biologyduring the purification process. Its stability was checked inmeth-
anolic extracts containing 0.1–0.5 mg/ml of the antibiotic, at
different pH values (3, 6, 7.5, and 9.5) and temperatures (4 and
40C). The antibiotic half-life at 40C was more than 1 month in
the 2–6 pH range, decreasing progressively at pHs from 6 to
7.5. At pH 9.5, the half-life was approximately 1 week at 4C
and 1 day at 40C, respectively.
Figure 1. Primary Structure of the Antibiotic Microbisporicin A1 and
A2Structure Determination of Microbisporicin A1 and A2
The structures assigned to microbisporicin A1 and A2 (Figure 1)
have been elucidated by spectroscopic and degradation stud-
ies. The investigation focused first on microbisporicin A2. The
1H NMR spectrum reflected a pattern typical for small peptide
molecules. The amino acid spin systems were identified and
assigned by analyzing double-quantum filtered correlation
spectroscopy (DQF-COSY) and total correlation spectroscopy
(TOCSY) experiments, as described by Bax and Davis (1985)
and Griesinger et al. (1988). Table 1 reports the proton chemical
shifts of the individual amino acids, together with their CHa-NH
coupling constants and amide proton temperature coefficients.
The experiments revealed that five proteinogenic amino acid
spin systems, Val, Leu, Pro, Asn, and Thr, occur only once. Gly
spin system appeared four times, and a 4-hydroxy-proline
(4-OHPro) was identified. Two aromatic ring systems were
assigned by examining the aromatic region of the DQF-COSY
spectrum. Some doublets and triplets, corresponding, respec-
tively, to a chloro-tryptophan (ClTrp) residue and to phenylala-
nine (Phe), were observed. As there was no mutual coupling,
connectivities between the aromatic protons and their backbone
protons could only be established through nuclear Overhauser
enhancement (NOE) spectroscopy (NOESY) experiments. In
addition, spin systems of some amino acids, characteristic of
lantibiotics, were present. Dha, Dhb, and 2-aminovinyl-cysteine
(AviCys) were found in the characteristic spectral region of
5.5–7.0 ppm (Wishart and Nip, 1998). Finally, the a-aminobutyric
acid (Abu) part of the Melan unit appeared once, whereas three
Lans (Ala-S-Ala) were identified. A majority of amide protons
were observed and assigned to the corresponding CHa, as
reported in Table 1.
To assign the peptide sequence, we investigated short-range
NOESY crosspeaks between the CHa, CHb, or amide proton of
(i) residue and the amide proton of the adjacent (i + 1) residue in
the peptide sequence (Wu¨thrich, 1986), denoted by aN, bN, and
NN, respectively. In microbisporicin A2, a sequence of such
NOEs could be traced for the majority of the 24 amino acid15, 22–31, January 2008 ª2008 Elsevier Ltd All rights reserved 23
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sequence Avi24-Ala23-Phe22-Ala21 was established with the
assigned low-field amide protons at 9.78 ppm (Phe22), 9.39
ppm (Asn20), and 9.34 ppm (Ala23); beginning with the Avi24
residue, four interresidue NOESY peaks with Ala21, Ala23, and
Phe22 were found. Moreover, correlations between NH Avi24-
CHa Ala23, NH Ala23-CHa Phe22, and NH Phe22-CHa Ala21
were identified. The sulfide ring E was elucidated on the basis
of the correlation between CHb Avi24 and CHb Ala21. The
Avi24-Ala21 bridge was also consistent with NOE and long-
range connectivities found between Avi24Hb and Ala21Hb pro-
tons. Similarly, it was possible to sequentially assign the rest of
the molecule by using the information from NOESY spectra
acquired at 313K and 293K, together with the heteronuclear mul-
tiple bond correlation (HMBC) data. The position of the sulfide
bridges could also be deduced from 13C-1H multiple-bond
correlations C-S-C-H between the two amino acids forming
the bridge and then confirmed by NOE crosspeaks between
b-protons in the Ala residues of the Lan. In microbisporicin A2,
the connectivities Ala3-Ala7, Ala13-Ala20, Ala18-Ala23, and
Abu8-Ala11 were observed in this way. The complete set of
interresidue NOE data are listed in Table S1 in the Supplemental
Data available with this article online. The carbon chemical shifts
of all amino acid residues are listed in Table 2. The 13C reso-
nances of all the carbons could be assigned without overlap by24 Chemistry & Biology 15, 22–31, January 2008 ª2008 Elsevier Ltdusing the heteronuclear multiquantum correlation (HMQC) and
HMBC spectra. A similar experimental approach was followed
to determine the structure of microbisporicin A1. In this case,
twin spin systems for all the amino acids were present due to
a slow conformational equilibrium observed in solution. Notwith-
standing the increased spectral complexity, proton chemical
shifts and the CHa-NH coupling constants were established
for the individual amino acids, as reported in Table S2. Interresi-
due NOE data are listed in Table S3 of the Supplemental Data.
Microbisporicin A1 and A2 differed only in the amino acid residue
in position 14. A 3,4-dihydroxy-proline (3,4-diOHPro) residue
was found in microbisporicin A1 in place of 4-OHPro in A2
(Figure 1).
Mass spectrometry (MS) analyses were performed on the
hydrolyzed and intact antibiotic to further confirm the structure
assigned by NMR. The liquid chromatography (LC)-MS analysis
of the acidic hydrolysis mixture showed the presence of the Lan,
Melan, Gly, Thr, Pro, Val, Phe, Leu, and Asp amino acids, the last
derived from Asn residue under the strong acidic conditions
applied for the hydrolysis. The residues Dha, Dhb, ClTrp, and
AviCys were not found, probably because of their instability
under these conditions. The peculiar 5-ClTrp was identified
when either A1 or A2 was hydrolyzed by using a protocol that
prevented its acidic degradation (Simpson et al., 1976). It coe-
luted with an authentic standard at 11.5 minutes and showedTable 1. Proton Chemical Shifts of the Individual Amino Acids Constituting Antibiotic Microbisporicin A2 Together with Their
J Coupling Constants and Amide Temperature Coefficients
Residue NH (ppm) CHa (ppm) CHb (ppm) Others (ppm) J (NH-CHa) (Hz) Dd/T (ppbK1)
Val1 — 3.94 2.27 Me: 1.06–1.08 —
Dhb2 — — 6.39 Me: 1.79 —
Ala3 7.86 4.62 3.25–2.94 5 10
ClTrp4 8.23 4.6 3.31–2.93 7.03,7.15,7.33,7.48, 10.4 7.7 6
Dha5 — — 5.54–6.04
Leu6 8.68 4.18 1.7–1.73 Me: 0.92–0.98; CHg: 1.63 8
Ala7 8.04 4.58 2.92–3.07 5.2
Abu8 8.31 — 3.36 Me: 1.17 10.2 4.2
Pro9 — 4.33 2.39–1.8 CHg: 1.83–2.07; CHd: 3.0–3.46 —
Gly10 8.44 4.36–3.52 4
Ala11 7.68 4.03 2.92–3.62 4
Thr12 8.1 4.18 4.39 Me: 1.3 5.2 8
Ala13 9.25 4.24 2.99–3.49 4
4-OHPro14 — 4.54 2.37–1.93 CHd: 3.6–3.86 —
Gly15 7.68 3.68–4.13 4.1
Gly16 8.49 3.39–4.29 3.3
Gly17 8.04 3.98–4.38 2.9
Ala18 8.68 4.43 3.26 8.1
Asn19 9.39 4.43 2.79–3.02 NH2g: 6.79–7.55 8
Ala20 8.89 4.19 3.11–3.81 10
Ala21 7.99 4.99 2.98–3.13 8.9 2.2
Phe22 9.78 4.3 3.3–2.98 7.23, 7.36 10
Ala23 9.34 4.15 2.64–3.43 2
Avi24 8.58 6.93 5.64 10.2
Microbisporicin A2 was dissolved in H2O/MeOH-d3 at 300K.All rights reserved
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detected in the hydrolysis mixture of microbisporicin A1 and A2.
The mass spectrum of the intact microbisporicin showed the
presence of two intense signals at m/z of 1124 and 1116,
corresponding to the double-charged ion [M + 2H]2+ (Figure 2)
of A1 and A2, respectively. In the full-scan spectrum range of
300–3000 mass units, the signals corresponding to the single-
charged ions [M + H]+ 2247 and 2231 were also present. The
calculated molecular weights 2246 and 2230 Da were consistent
with the assigned structures of A1 and A2.
Secondary Structure of Microbisporicin
We gained insight into the secondary structure of the antibiotic
by analyzing the amide proton temperature coefficients, listed
in Table 1 for microbisporicin A2, and solvent accessibility.
Hydrogen bond formation typically stabilizes the exchangeable
backbone amide protons and therefore reduces the exchange
rate with the bulk solvent. Such stability can also be achieved
when solvent accessibility is reduced as a result of steric con-
straints. Information about the extent to which hydrogens are
bonded or sequestered from the solvent is gained by simply as-
Table 2. 13C Chemical Shift of the Individual Amino Acids













Val1 170 59.5 30.95 Me: 17.89, 18.72
Dhb2 165.7 129.2 132.9 Me: 13.6
Ala3 54.45 37.6
ClTrp4 56.87 27.4 2) 126.8; 3) 109.7;
4) 118.6; 5) 124.9;
6) 122.4; 7) 113.8;
8) 135.6; 9) 129.1
Dha5 167.1 134.8 106.7
Leu6 54.14 40.2 25.6 Me: 21.9, 22.9
Ala7 56.8 35.2
Abu8 57.92 49.77 Me: 21.9
Pro9 — 61.79 29.36 26.84 CHd: 49.22
Gly10 43
Ala11 55.8 37.1
Thr12 59.72 68.53 Me: 20.12
Ala13 — 37.3








Phe22 60.45 37.86 137.3; 2) 129.7;
3) 130.1; 4) 128.1
Ala23 54.5 32.36
Avi24 130.5 105.3Chemistry & Biologysessing the temperaturedependencyof the amideprotonchemical
shifts (Cierpicki and Otlewski, 2001; Hsu et al., 2003). A low depen-
dency of the amide chemical shift on temperature in an aqueous
environment (temperature coefficients, Dd/Dt > 2.5 ppb/K)
is usually indicative of the presence of a stable hydrogen
bond, while solvent-accessible amide protons are more sensi-
tive to temperature change (Dd/Dt < 5 ppb/K). Based on the
criteria listed above, stable amide protons with low solvent
accessibility were identified for Ala21, Ala23, and Gly17,
whereas Ala3, Ala20, and Phe22 were more strongly influenced
by the solvent. In addition, the sequential NOEs used to assign
the resonances (see Table S1) provided further evidence for
regions of regular secondary structure in microbisporicin A2.
The continuous stretch of medium-range sequential NN connec-
tivities from residue Ala11 to Avi24 suggests that this region may
adopt a compact rather than an extended conformation. In
particular, the observed crosspeaks between residues Abu8-
Phe22 and Pro9-Ala20 were indicative of a globular 3D structure
of this region. In the case of microbisporicin A1, the presence of
the 3,4-diOHPro in position 14 further increased the rigidity of
the molecule. This was indicated by the slow conformational
Figure 2. Mass Spectra of Microbisporicin A1 and A2 Obtained from
Infusion Experiments
(A) Full-scan, low-resolution spectrum and (B) zoom-scan, high-resolution
spectrum. Two doubly protonated ions [M + 2H]2+ corresponding to microbis-
poricin A1 and A2 have m/z values at 1124 and at 1116 respectively. M/z at
1126 corresponded to the [MA2 + H
+Na]2+ ion.15, 22–31, January 2008 ª2008 Elsevier Ltd All rights reserved 25
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possible to distinguish and assign two separate conformers
(Table S2). Further work is needed to determine the overall mo-
lecular conformations with distance constraints derived from
NOESY experiments.
Figure 3. Inhibition Test of Macromolecular Syntheses in Staphylo-
coccus aureus
Effect of microbisporicin on DNA (open diamonds), RNA (open squares),
protein (open triangles), and PG syntheses (closed circles).Mode of Action of Microbisporicin
Microbisporicin was active against S. aureus and inactive
against its L forms that lacked a functional cell wall. The cell
wall target was confirmed by testing the antibiotic in experiments
of macromolecular syntheses in S. aureus. Figure 3 shows that
PG biosynthesis was completely blocked by microbisporicin at
a concentration of 1 mg/ml. At this concentration, the effects
on DNA, RNA, and protein syntheses were marginal. The inhibi-
tion patterns for microbisporicin were quite similar to those
previously reported for glycopeptides and other lantibiotics,
such as planosporicin and actagardine (Castiglione et al.,
2007). However, planosporicin and actagardine blocked cell
wall synthesis at higher concentrations of 10 and 100 mg/ml,
respectively. Indeed, lantibiotic nisin inhibited all macromolecu-
lar syntheses at the same concentration (1 mg/ml), which is
consistent with its disrupting action on membrane integrity
(Castiglione et al., 2007).
The microbisporicin’s mode of action was confirmed by the
analysis of its effect on the cytoplasmic pool of UDP-linked PG
precursors in Bacillus megaterium.When cells of B. megaterium
were treated with microbisporicin, the cell wall precursor,
uridinediphospho-N-acetylmuramyl-L-Ala-D-Glu-mDap-D-Ala-
D-Ala, accumulated in their hydrolyzates. This compound, which
could not be detected in untreated cells, eluted with a retention
time of 13.4 min in the LC-MS conditions described in the Exper-
imental Procedures. Its positive and negative ion mode MS
spectra and MS/MS fragmentation profile (data not shown) are26 Chemistry & Biology 15, 22–31, January 2008 ª2008 Elsevier Ltdidentical to the ones that we previously reported for planospori-
cin- or vancomycin-treated cells (Castiglione et al., 2007). The
accumulation of the UDP-MurNAc-pentapeptide is consistent
with the data reported in a variety of bacteria treated with cell
wall inhibitors acting at steps subsequent to its cytoplasmic
synthesis, such as ramoplanin, vancomycin, teicoplanin,
mannopeptimycins (Billot-Klein et al., 1997; Ruzin et al., 2004),
and lantibiotics mersacidin and actagardine (Brotz et al., 1997,
1998a).
Antimicrobial Activity
Table 3 presents the spectrum of microbisporicin’s antibacterial
activity against a panel of important human pathogens. Individ-
ual factors A1 and A2 showed substantially identical activity
against the entire panel (data not shown). Microbisporicin was
active against major Gram-positive pathogens, including
MRSA and vancomycin-resistant enterococci (VRE). Minimal
inhibitory concentrations (MICs) were in the range of % 0.13–
4.0 mg/ml against Staphylococci, Streptococci, Enterococci,
and Lactobacilli, indicating a potency comparable or superior
to that of vancomycin and teicoplanin (French, 2006). The antibi-
otic was also very active against anaerobic Clostridia (MICs %
0.13 mg/ml) and Propionibacteria (MICs % 0.13–4 mg/ml). The
activity of microbisporicin against aerobic and anaerobic
Gram-positive bacteria appeared consistently superior with
respect to the comparator lantibiotics planosporicin, actagar-
dine, and mersacidin, and also with respect to the most active
nisin. Escherichia coli or other enterobacteria were insensitive
to lantibiotics. However, microbisporicin was more active than
the comparators against theGram-negativeMoraxella catarrhalis,
Neisseria spp., and Haemophilus influenzae. Consistent with
the mode of action of cell wall inhibitors, no activity for microbis-
poricin was observed against S. aureus L form (L3751) and the
eukaryote Candida albicans.
Efficacy in Animal Models
Antibiotic microbisporicin was tested against murine septicemia
caused by S. aureus Smith 819 ATCC 19636 (MIC% 0.13 mg/ml).
Antibiotic microbisporicin protected mice with an antibiotic dose
at 50% of in vivo efficacy (ED50) of 2.1 mg/kg. This level of
protection was observed both after intravenous (iv) and subcuta-
neous (sc) administration. In the same infection model, the
reference drug, vancomycin (MIC = 0.5 mg/ml) showed an ED50
of 0.9 mg/kg by sc administration. Moreover, animals treated
with high doses of microbisporicin (R200 mg/kg) survived,
thus indicating low acute toxicity either iv or sc.
DISCUSSION
This paper presents the novel and potent lantibiotic, microbis-
poricin. It was found through a screening process devised to
discover selective PG synthesis inhibitors: (1) produced by un-
common actinomycetes; (2) essentially not cross-resistant with
b-lactams and glycopeptides; and (3) effective against infections
caused by Gram-positive pathogens. We found microbisporicin
in a group of antibiotics that fulfilled these selection criteria.
The structure of microbisporicin is substantially different from
any of the 50 previously described lantibiotics (Chatterjee et al.,
2005; Jung, 2006). It was produced by an actinomycete speciesAll rights reserved
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A1 and A2, which differ in a hydroxylic group on the hydroxy-pro-
line at position 14, and show an equal mode of action and antimi-
crobial spectrum. Microbisporicin A1 and A2 are peptides with
a molecular weight of 2246 and 2230 Da, respectively. The
24-mer peptides are ribosomally synthesized and subsequently
modified to introduce hydroxylated Pro and chlorinated Trp
residues, which have never been detected in lantibiotics. Five
thioether intramolecular bridges (a single Melan, three Lan, and
the AviCys residue) are predictive of conformational constraints.
Indeed, NMR studies showed that the structure comprises
a globular domain from Ala11 to Avi24, created by the formation
of thioether bonds between residues Ala13 and Ala20 (ring C),Chemistry & BiologyAla18 and Ala23 (ring D), and Ala21 and Cys24 terminal end
(ring E). In this region, a certain degree of conformational flexibil-
ity was observed in the ring formed by the eight residues,
Ala13–Ala20, where three sequential Gly are located. However,
microbisporicin does not contain any conserved motif resem-
bling the type B globular lantibiotic actagardine. A limited simi-
larity with the globular lantibiotic mersacidin could be identified
in the sequence of three Gly residues following Pro6 in mersaci-
din and 4-OH Pro14 in microbisporicin A2 (3,4-diOH Pro in A1),
and between the C-terminal AviCys of microbisporicin and
AviMeCys of mersacidin. In turn, the C-terminal ring of microbis-
poricin is nearly identical to the C-terminal AviCys in the type AI
lantibiotics epidermin and gallidermin (Chatterjee et al., 2005;Table 3. Antimicrobial Activity of Microbisporicin in Comparison to Planosporicin, Actagardine, Mersacidin, and Nisin
Strain
MIC (mg/ml) Microbisporicin Planosporicin Actagardine Mersacidin Nisin
L100 Staphylococcus aureus ATCC6538P %0.13 2 32 4 0.5
L3751 Staphylococcus aureus L form >128 >128 >128 64 16
L819 Staphylococcus aureus Smith
ATCC19636
%0.13 16 32 4 2
L1400 Staphylococcus aureus MRSA %0.13 16 16 8 2
L613 Staphylococcus aureus MRSA %0.13 32 16 64 8
L3798 Staphylococcus aureus VISA 2 128 128 128 32
L3797 Staphylococcus aureus VISA met-r 2 >128 >128 128 8
L3798 Staphylococcus epidermidis
ATCC12228
%0.13 32 128 16 2
L1729 Staphylococcus haemolyticus met-r 8 >128 >128 8 4
L49 Streptococcus pyogenes %0.13 0.5 2 n.d. n.d.
L44 Streptococcus pneumoniae %0.13 4 32 4 0.25
L559 Enterococcus faecalis 1 16 32 32 4
L560 Enterococcus faecalis Van A 0.5 64 128 64 4
LA533 Enterococcus faecalis Van A 1 128 16 32 4
L568 Enterococcus faecium 2 64 64 64 2
L569 Enterococcus faecium Van A 1 128 128 64 2
LB518 Enterococcus faecium Van A 2 >128 >128 128 1
L884 Lactobacillus garviae %0.13 4 4 16 n.d.
L148 Lactobacillus delbrueckii ATCC04797 4 16 >128 >128 >128
L3607 Clostridium perfringens ATCC13124 %0.125 %0.25 4 8 %0.13
L4018 Clostridium difficile %0.125 1 4 8 %0.13
L4043 Clostridium butyricum %0.125 n.d. n.d. n.d. n.d.
Propionibacterium granulosum ATCC25564 0.03 n.d. n.d. n.d. n.d.
L1329 Propionibacterium acnes 0.5 n.d. n.d. n.d. n.d.
Propionibacterium limphophylum
ATCC27250
0.015 n.d. n.d. n.d. n.d.
L970 Haemophilus influenzae ATCC19418 32 >128 >128 >128 >128
L76 Moraxella catarrhalis ATCC8176 0.25 1 32 2 1
L1613 Neisseria meningitidis ATCC13090 0.5 >128 >128 >128 8
L997 Neisseria gonorrhoeae 0.25 >128 >128 >128 4
L47 Escherichia coli >128 >128 >128 n.d. >128
L145 Candida albicans >128 >128 >128 n.d. >128
ATCC, American Type Culture Collection; met-r, methicillin-resistent; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant Staphylococ-
cus aureus; n.d., not detected; Van A, vancomycin-resistent; VISA, vancomycin-intermediate-resistent Staphylococcus aureus.
MICs were determined by broth microdilution assay (NCCLS, 1990) according to the procedure described in the Experimental Procedures.15, 22–31, January 2008 ª2008 Elsevier Ltd All rights reserved 27
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the type AII lantibiotic cypemycin (Chatterjee et al., 2005;
Komiyama et al., 1993). The topology of the A, B, D, and E rings
of microbisporicin is nearly identical to epidermin (Allgaier et al.,
1986; Bonelli et al., 2006). Actually, the C ring is different and, in
part, resembles that of ericin A, also a type AI lantibiotic (Chat-
terjee et al., 2005; Stein et al., 2002). Microbisporicin is similar
to the recently discovered planosporicin (Castiglione et al.,
2007) in the number of amino acid residues and intramolecular
thioether bridges, but the amino acid composition and
sequence and the positions of the five rings are definitively
different. Only the N-terminal three amino acids (NH2-Val-Dhb-
Ala) are similar to planosporicin (NH2-Ile-Dhb-Ala), which is in
turn identical to nisin (Castiglione et al., 2007). Interestingly,
the N-terminal portion of microbisporicin, from Val1 to Ala11,
shows a great similarity in amino acid sequence and bridge
formation with the N-terminal part of the linear type AI lantibiot-
ics nisin, subtilin, epidermin, and gallidermin (Chatterjee et al.,
2005; Cotter et al., 2005; Allgaier et al., 1986; Bonelli et al.,
2006). This N-terminal sequence was found to be crucial for nisin
and epidermin binding to the lipid II pyrophosphate region, as
demonstrated by specific mutations drastically reducing antimi-
crobial activity (Brotz et al., 1998b; Hsu et al., 2004; Wiedemann
et al., 2001). Moreover, the nisin binding to lipid II was antago-
nized by the N-terminal 1–12 fragment of nisin (Chan et al.,
1996). It would be interesting to investigate whether the N-termi-
nal region of microbisporicin has the same function as in nisin
and epidermin. Microbisporicin contains an organic chlorine
substituent at an aromatic ring, which is different from other
lantibiotics. It is worth noting that other chemical classes of
antibiotics acting on lipid II, such as glycopeptides and
ramoplanin, contain a similar chlorine substituent on an aromatic
ring, the lipophylic nature of which may contribute to their affinity
for the membrane compartment (Parenti et al., 1990; Walsh,
2003).
Considering the mode of action, microbisporicin primarly
blocked PG synthesis differently from nisin, which blocked all
the principal macromolecular syntheses as a result of rapid
cell membrane depolarization (Castiglione et al., 2007). Micro-
bisporicin was active at concentrations significantly lower
than those of mersacidin-actagardine-planosporicin lantibiotics
and comparable to the effective concentrations of nisin. As
previously reported for planosporicin and glycopeptides (Cas-
tiglione et al., 2007), microbisporicin caused accumulation of
the cytoplasmic UDP-pentapeptide precursor of PG in growing
bacterial cells. Such accumulation indicates that the multistep
assembly of PG located at the membrane is inhibited; this has
been observed in a series of antibiotics acting on this phase
(Brotz et al., 1998a, 1997; Billot-Klein et al., 1997; Ruzin
et al., 2004). The bactericidal activity of nisin has been gener-
ally found to be superior to other lantibiotics on the basis of
MIC comparisons. Superior bactericidal activity has been
explained by taking into account nisin’s dual mechanism of
action, mediated by lipid II binding and resulting in cell wall
inhibition and pore formation (Breukink et al., 1999; Hasper
et al., 2006). It has been recently reported that pore-forming
capacity of the 22 amino acid long gallidermin and epidermin
varies depending on the target strains, and that some microor-
ganisms remain susceptible in spite of missing pore formation28 Chemistry & Biology 15, 22–31, January 2008 ª2008 Elsevier Ltd(Bonelli et al., 2006). It thus appears that the multiple activities
may combine differently in lantibiotics. The discovery of micro-
bisporicin, original in structure and specifically acting on the
cell wall pathway, may provide additional insights into the mo-
lecular determinants of the biological activity of lipid II-targeting
antibiotics.
Indeed, the spectrum of activity of microbisporicin covered
important aerobic and anaerobic Gram-positive pathogens.
MRSA and VRE were susceptible, which is consistent with the
selection criteria applied in the original screening. The activity
of microbisporicin appeared comparable to or better than those
of reference antibiotics, such as vancomycin and teicoplanin
(French, 2006). With respect to nisin, the spectrum of activity
was comparable or enhanced. Microbisporicin showed activity
against the Gram-negative bacteria M. catarrhalis, Neisseria
spp., and H. influentiae, which were insensitive to most of the
lantibiotics and moderately susceptible to nisin. The antibiotic
showed good efficacy in vivo after a single administration in an
experimental infection model caused by S. aureus in a mouse.
ED50s were identical after iv and sc administration. This may
indicate that distribution and bioavailability are comparable
between the two administration routes. These results, together
with those that will be described elsewhere (P.C. et al.,
unpublished data) on the efficacy of microbisporicin in different
animal models of infection, indicate that it is a promising antibac-
terial for the systemic treatment of serious nosocomial infections
caused by multidrug-resistant pathogens.SIGNIFICANCE
Microbisporicin, produced by an uncommon actinomycete
and discovered in the course of a biological activity-guided
screening for bacterial cell wall synthesis inhibitors others
than b-lactams and glycopeptides, is the most potent
antibacterial among the known lantibiotics. Its spectrum of
activity coversmost of the Gram-positive isolates ofmedical
importance and some Gram-negative pathogens, which dif-
fers from other lantibiotics. Considering also its efficacy
in vivo, microbisporicin represents a promising antibiotic.
Its structure is substantially different from any other antibi-
otic described. Microbisporicin is produced as two structur-
ally related and similarly active 24 amino acid-long polypep-
tides, containing two posttranslational modifications and
five thioether intramolecular bridges. The sequences of the
N-terminal and C-terminal portions of microbisporicin and
the topology of A, B, D, and E rings show great similarity
with the 22 amino acid-long lantibiotics epidermin and
gallidermin. The 1–11 N-terminal sequence is very similar
to that of nisin, which was found to be crucial for lantibiotic
binding to the lipid II pyrophosphate region. It would be
interesting to investigate whether the N-terminal region of
microbisporicin has the same function and may account
for its superior bactericidal activity in comparison with the
other known lantibiotics. Microbisporicin’s mode of action
consists in the selective inhibition of bacterial cell wall
synthesis. The discovery of this lantibiotic provides addi-
tional insights into themolecular determinants of the biolog-
ical activity of lipid II-targeting antibiotics.All rights reserved
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Bacterial Strains
B. megaterium ATCC 13632 and S. aureus 209 ATCC 6538P (L100) were
purchased from the American Type Culture Collection (ATCC; Manassas
VA). L-form cells were prepared (L3751) from L100 as previously described
(Somma et al., 1977). S. aureus Smith 819 ATCC19636 and other clinical
isolates were maintained in the Lepetit Culture Collection (L) at Vicuron
Pharmaceuticals, Gerenzano, Italy. Microbispora sp., the producer of micro-
bisporicin (initially patented as Antibiotic 107891 [Lazzarini et al., 2005]), was
previously isolated in the Vicuron laboratory from a soil sample. It was depos-
ited as Microbispora sp. ATCC PTA-5024 (ATCC).
Fermentation
Microbispora sp. ATCC PTA-5024 was cultivated at 30C and then shaking
this culture at 200 rpm in 500 ml Erlenmeyer flasks containing 100 ml of
seed medium AF/MS (in g/l: dextrose, 20; yeast extract, 2; soybean meal, 8;
NaCl, 1; and CaCO3, 4; pH adjusted to 7.3), or in Chemap-Braun 20 l fermen-
ters containing 15 l of the same medium, at 30C and stirring at 600 rpm and
0.5 vvm (gas volume/liquid reactor volume/min) aeration. For fermentation,
300 l bioengineering fermenters were used that contained 200 l of the produc-
tion medium, M8 (in g/l: starch, 20; glucose, 10; yeast extract, 2; hydrolyzed
casein, 4; meat extract, 2; and CaCO3, 3; pH adjusted to 7.0), inoculated
with 7% preculture, at 28C–30C, stirred at 180 rpm, and aerated at
0.5 vvm. The production of microbisporicin was monitored by HPLC, as de-
scribed below.
Isolation of Microbisporicin A1 and A2
Broth was harvested after 90–100 hours of fermentation and then filtered by
tangential filtration (0.1 mm pore size membrane, Koch Carbo-Cor; Koch
Membrane Systems, Inc.). The filtrate was stirred with 2.3% (v/v) Diaion HP
20 polystyrene resin (Mitsubishi Chemical Co.). The resin was then recovered,
washed batch-wise with methanol:water (2:3, v/v), and eluted with metha-
nol:n-butanol:water (9:1:1, v/v/v). The fractions containing the lantibiotic
were pooled and concentrated under vacuum to a residue of raw material
that was dissolved in n-butanol. This solution was extracted three times with
water, reconcentrated under vacuum, and dissolved in petroleum ether. The
antibiotic in the mycelium fraction was extracted by adding an equal volume
of methanol, and was recovered accordingly after vacuum evaporation of
the solvent. Crude antibiotic was purified by chromatography on an IST C8
703 460 mm column (EC; 40–70 mm particle size; 60 A˚ pore size; International
Sorbent Technology), which was eluted by a Bu`chi B-680 Medium Pressure
Chromatography System with a 60 minute (25 ml/min flow rate) linear gradient
from 20% to 60%of phase B (phase A: acetonitrile, 20mMammonium formate
buffer [pH 6.6] 10:90 [v/v]); phase B: acetonitrile, 20 mM ammonium formate
buffer [pH: 6.6], 90:10 [v/v]). The eluted fractions containing lantibiotics were
pooled, concentrated, and lyophilized twice to generate a solid preparation
of microbisporicin. Individual, pure A1 and A2 factors were obtained by
preparative HPLC on a Symmetry Prep C18 Waters column (7 mm particle
size, 7.8 3 300 mm). Microbisporicin A2 was purified by isocratic elution at
a flow rate of 7 ml/min with 100 mM ammonium formate buffer (pH 4):acetoni-
trile (82.5:17.5, v/v). Microbisporicin A1 was purified by a 25 minute linear
gradient elution from 30% to 45% of phase B (3.5 ml/min flow rate). Phase A
was 25 mM ammonium formate buffer (pH 4.5):acetonitrile (95:5, v/v), and
phase B was acetonitrile. The fractions from repeated chromatographic runs
were pooled, concentrated under vacuum, and lyophilized sequentially three
times to yield the purified factors as a white powder.
Analytical Chromatography
The fermentation andpurification processesweremonitoredon aWatersHPLC
instrument equipped with a Waters Symmetry Shield RP8 250 3 4.6 mm
column, 5 mm particle size, and a Symmetry C18 (5 mm) 3.9 3 20 mm
precolumn, both maintained at 50C, and eluted at 1 ml/min flow rate accord-
ing to the following multistep gradient program: 8 min at 30% phase B (aceto-
nitrile) in phase A (acetonitrile:100 mM ammonium formate pH 4.5 buffer, 5:95
[v/v]), followed by a 20minute linear gradient from 30% to 45%. Detection was
at 282 nm. Microbisporicin A1 and A2 factors typically eluted after 16.3 and
16.8 minutes, respectively.Chemistry & BiologyLC-MS and MS/MS Analyses
LC-MS and MS/MS experiments were performed with a ThermoQuest
Finnigan LCQ Deca mass detector equipped with an ESI interface and Thermo
Finnigan Surveyor MS pump, photo diode array detector (PDA) (UV6000;
Thermo Finnigan), and an autosampler, as described previously (Meiring
et al., 2002). The MS spectra were obtained by electrospray ionization, both
in positive and negative mode, under the conditions described by Castiglione
et al. (2007). In the infusion experiments, microbisporicin A1 or A2 was diluted
to 0.1 mg/ml in water:acetonitrile (50:50, v/v) with 0.5% acetic acid (v/v). The
ThermoQuest Finnigan LCQ Deca mass detector was previously tuned and
calibrated in electrospray mode and used in infusion mode at 10 ml/min.
Hydrolysis and Amino Acid Analysis
Microbisporicin A1 or A2 (1 mg) was completely hydrolyzed by treatment for
24 hours in 6 N HCl at 105C. The mixture of hydrolyzed amino acids was
treated with N-hydroxysuccinimide-activated heterocyclic carbamate Waters
AccQ-Fluor Reagent Kit (Pawlowska et al., 1993), and was then analyzed by
LC-MS, as previously described by Castiglione et al. (2007). To determine
the levels of 5-ClTrp, microbisporicin A1 or A2 (1 mg) was incubated for
16 hours in 0.6 ml of 4 Nmethanesulfonic acid containing 0.2% (w/v) 3-(2-ami-
noethyl)indole at 115C, as described by Simpson et al. (1976). The hydroly-
sate, neutralized with 5 N NaOH and diluted in water, was analyzed by LC-
MS. The separation was performed on a Waters Symmetry Shield C18 250
3 4.6 mm column, 5 mm particle size, equipped with a Symmetry C18 (5 mm)
3.93 20mmprecolumn and eluted at 1ml/min flow rate with a 25minute linear
gradient from 0% to 50% of phase B (acetonitrile) in phase A (acetonitrile:25
mM ammonium formate [pH 4.5] buffer, 5:95 [v/v]). Detection was at 280
nm. The effluent from the column was split between PDA and MS detectors.
The MS parameters were the same as described previously here, and the
spectra were acquired in the 100 to 700 mass unit range. Under these condi-
tions, standard samples of DL-tryptophan (Merck KGaA, Darmstadt, Ger-
many) and 5-chloro-DL-tryptophan (Biosynt AG, Staad, Switzerland) typically
eluted after 8.1 and 11.5minutes, respectively, corresponding to [M +H]+ atm/
z 205 and 239, respectively.
NMR Spectroscopy
Microbisporicin dissolved poorly in water and showed some instability in
dimethyl sulfoxide (DMSO). Therefore, the antibiotic was dissolved in amixture
of methanol/water acidified with drops of 0.01 N HCl. In these conditions, no
degradation was observed when microbisporicin was incubated at tempera-
tures ranging from 288K to 313K. NMR spectroscopic analyses were
performed on the following samples: (1) 5.1 mg microbisporicin A1 factor dis-
solved in 0.6 ml of MeOH:d3/H2O (4:1, v/v); (2) 5.1 mg microbisporicin A2 dis-
solved in 0.6 ml of MeOH:d3/H2O (4:1, v/v.); and (3) 6 mg microbisporicin A2
dissolved in 0.6 ml CD3CN:D2O (1:1, v/v.). The following experiments were
performed on all three samples: 1H 1D spectrum, 2D DQF-COSY, TOCSY,
and NOESY, with a watergate presaturation sequence, at 300K–290K. The
NOESY experiment was conducted with a mixing time of 300 ms. 2D spectra
were recorded with a spectral width of 12 ppm, 16 scans, 1024 T1-weighted
increments, and 4096 T2-weighted complex data points. Heteronuclear
13C-{1H}, HSQC, and HMBC experiments were performed at 313K on sample
3. For the 13C-{1H} 1D spectrum, a sweep width of 220 ppm was used; 140K
scans were accumulated, with a relaxation delay of 2 seconds. The HMQC
and HMBC spectra were acquired with 1024 T1-weighted increments and
2048 T2-weighted complex data points, with a sweep width of 10 ppm in
the proton and 220 ppm in the carbon dimension. These data were acquired
on a Bruker AVANCE 750 MHz spectrometer equipped with a Z-gradient
probe.
LC-MS Analyses of the Cytoplasmic PG Precursor Pool
B. megateriunm ATCC 13632 was cultivated in 100 ml Difco Mueller Hinton
broth (MHB) at 37C to an A540 nm of 0.7. The culture was then divided into
equal portions supplemented with antibiotic concentrations that were at least
100-fold greater than the MICs against B. megaterium. Vancomycin, teicopla-
nin, microbisporicin, planosporicin, and chloramphenicol were added at
concentrations of 20, 20, 100, 100, and 100 mg/ml, respectively. The analysis
of the cytoplasmic PG precursor pool was performed according to Kohlrausch
and Holtje (1991). Briefly, after a 60 minute incubation at 37C, the cells were15, 22–31, January 2008 ª2008 Elsevier Ltd All rights reserved 29
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20minutes. After cooling first at room temperature and then in ice, the suspen-
sion was then centrifuged at 39,000 3 g for 30 minutes. The supernatant was
lyophilized and dissolved in 0.1 volumes of water adjusted to pH 3 with formic
acid. The samples were analyzed by reversed-phase HPLC and ESI-MS.
Cytoplasmic PG precursors were separated on a C18 250 3 4.6 mm column
(Phenomenex Luna), 5 mm particle size, eluted at a 1 ml/min flow rate with
a 2 minute, 100% Phase A (2% acetonitrile:97.9% water:0.1% formic acid.
v/v/v) and then a 50 minute linear gradient to 100% phase B (95% acetoni-
trile:4.915% water:0.085% formic acid, v/v/v). Column temperature was
22C. The effluent from the column was split in a ratio of 1:5 between PDA
and MS detectors, as described previously here.
Inhibition of Macromolecular Synthesis
S. aureus 209 ATCC 6538P (L100) was cultivated in Iso-Sensitest broth (ISS;
Oxoid Ltd.) overnight at 37C. The culture was then diluted 1:1 (v/v) in Davis
Mingioli broth/ISS. At an A540 nm of 0.4, macromolecular syntheses (DNA,
RNA, protein, and PG) were monitored by incorporating the appropriate
radioactive precursors: for DNA synthesis, [3H]-thy (5 mCi/ml), with 0.1 g/l
unlabeled adenosine; for RNA synthesis, [5,6 3H]-Ura (2 mCi/ml); for protein
synthesis, L-[3H]-leucine (10 mCi/ml); and for PG, N-acetyl-D-[1-3H] glucos-
amine (1 mCi/ml), with 3.5 mg/l unlabeled N-acetylglucosamine. Of the result-
ing solutions, 100 ml were dispensed in 96-well microplates containing 10 ml of
increasing concentrations of microbisporicin, planosporicin, teicoplanin, acta-
gardine, or nisin. After 20 minutes of incubation at 37C, 0.1 ml ice-cold 20%
(w/v) trichloroacetic acid (TCA) was added to precipitate macromolecules.
After 30 minutes at 4C, the TCA precipitate was collected on glass fiber filters
(Filtermat A; Wallac) with a 96-well cell harvester (Wallac), and radioactivity
was determined in a b-plate scintillation counter (Wallac).
MIC Determinations
In vitro antimicrobial activity was determined by a brothmicrodilution assay, as
recommended by the National Committee for Clinical Laboratory Standards
(NCCLS, 1990). The growth media utilized to determine the MIC were: cat-
ion-adjusted Difco MHB for Staphylococci, Enterococci, Bacilli,M. catarrhalis,
and E. coli; Todd Hewitt broth for Streptococci; LactobacilliMRS broth (MRS)
for Lactobacilli; GC medium plus 1% (v/v) Isovitalex plus 1% (v/v) hemine for
Neisseria; Brain Hearth Infusion for H. influentiae; Brucella broth containing
cysteine (0.5 g/l) for Propionibacteria; Wilkins Chalgren broth for Clostridia;
and RPMI-1640 medium for C. albicans. Comparison of microbisporicin’s
activity versus S. aureus 209 ATCC 6538P (L100) and to its L form cells
(L3751) was performed according to the cell wall assay described by
Castiglione et al. (2007). Reversion of antimicrobial activity against S. aureus
209 ATCC 6538P (L100) was measured after adding b-lactamases coktail
(Castiglione et al., 2007) or 2 mg/ml of 3-amino-caproyl-D-Ala-D-Ala, a glyco-
peptide affinity resin prepared as described previously (Corti et al., 1985).
Experimental Septicemia
Female outbred ICR (CD-1) mice (Harlan Italia) weighing 23–25 g were infected
intraperitoneally with 106 cells of S. aureus Smith 819 ATCC 19636 per
mouse in 0.5 ml of bacteriological mucin (Difco). Microbisporicin was sus-
pended in amedium composed of 10%DMSO (v/v), 10% (w/v) b-hydroxy-pro-
pyl cyclodextrin (Sigma), and 80% (v/v) of 5% (w/v) glucose in water at a final
concentration from 5 to 10 mg/l. It was administered iv or sc within 10–15
minutes after infection. Vancomycin was used as the reference drug and
was administered sc. The ED50 was calculated by the Spearman-Ka¨rber
method (Finney, 1952) from the percentage of animals surviving to the seventh
day at each dose. A group of eight mice was treated for each experimental
condition.
Supplemental Data
Supplemental Data, including three additional tables, are available with this
article online at http://www.chembiol.com/cgi/content/full/15/1/22/DC1/.
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